000169207 001__ 169207
000169207 005__ 20260223164759.0
000169207 0247_ $$2doi$$a10.1080/09546634.2017.1395794
000169207 0248_ $$2sideral$$a148256
000169207 037__ $$aART-2018-148256
000169207 041__ $$aeng
000169207 100__ $$aCarretero, G.
000169207 245__ $$aRedefining the therapeutic objective in psoriatic patients candidates for biological therapy
000169207 260__ $$c2018
000169207 5060_ $$aAccess copy available to the general public$$fUnrestricted
000169207 5203_ $$aThe advances in psoriasis management currently allow achieving a good control of the disease. In particular, with the latest developed molecules, available evidence suggests that it is possible to pose an ambitious therapeutic goal, such as a Dermatology Life Quality Index 0/1, a Physician Global Assessment 0/1, or a Psoriasis Area and Severity Index 90/100 response. However, patients often fail to achieve the complete clearance of their cutaneous lesions or the improvement of disease factors that impair their quality of life. To optimize the treatment of psoriasis, it is not enough to define precisely the therapeutic objective, but also to adapt the therapeutic strategy to make the necessary modifications in case of not achieving it at the time point (at the end of the induction phase, or every 3–6 months) to be agreed with the patient (the so-called treat-to-target approach). In the present report, based on the Delphi methodology, 11 dermatologists from the Spanish Psoriasis Group addressed key issues that could be involved in the achievement and maintenance of the therapeutic goals of patients with moderate to severe psoriasis. The document provides 27 consensus statements intended to support clinical decision-making by healthcare professionals for patients who might be candidates to receive biologic therapy.
000169207 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000169207 590__ $$a2.112$$b2018
000169207 591__ $$aDERMATOLOGY$$b32 / 65 = 0.492$$c2018$$dQ2$$eT2
000169207 592__ $$a0.813$$b2018
000169207 593__ $$aDermatology$$c2018$$dQ1
000169207 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000169207 700__ $$aPuig, L.
000169207 700__ $$aCarrascosa, J. M.
000169207 700__ $$aFerrándiz, L.
000169207 700__ $$aRuiz-Villaverde, R.
000169207 700__ $$ade la Cueva, P.
000169207 700__ $$aBelinchon, I.
000169207 700__ $$aVilarrasa, E.
000169207 700__ $$adel Rio, R.
000169207 700__ $$aSánchez-Carazo, J. L.
000169207 700__ $$aLópez-Ferrer, A.
000169207 700__ $$aPeral, F.
000169207 700__ $$aArmesto, S.
000169207 700__ $$aEiris, N.
000169207 700__ $$aMitxelena, J.
000169207 700__ $$aVilar-Alejo, J.
000169207 700__ $$0(orcid)0000-0001-8789-6783$$aAra Martin, M.$$uUniversidad de Zaragoza
000169207 700__ $$aSoria, C.
000169207 700__ $$a
000169207 7102_ $$11007$$2183$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cÁrea Dermatología
000169207 773__ $$g29, 4 (2018), 334-346$$pJ. derm. treat.$$tJOURNAL OF DERMATOLOGICAL TREATMENT$$x0954-6634
000169207 8564_ $$s1127844$$uhttps://zaguan.unizar.es/record/169207/files/texto_completo.pdf$$yPostprint
000169207 8564_ $$s1323480$$uhttps://zaguan.unizar.es/record/169207/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000169207 909CO $$ooai:zaguan.unizar.es:169207$$particulos$$pdriver
000169207 951__ $$a2026-02-23-14:54:31
000169207 980__ $$aARTICLE